Department of Digestive Surgery, Centre Magellan - CHU Bordeaux, Bordeaux, France.
Department of Pathology, Hopital Pellegrin - CHU Bordeaux, Bordeaux, France.
Ann Surg. 2021 Nov 1;274(5):843-850. doi: 10.1097/SLA.0000000000005108.
Our aim was to determine independent risk factors of clinical bleeding of hepatocellular adenoma (HCA) to define a better management strategy.
HCA is a rare benign liver tumor with severe complications: malignant transformation that is rare (5%-8%) and more often, hemorrhage (20%-27%). To date, only size > 5 cm and histological subtype (possibly sonic hedgehog) are associated with bleeding, but these criteria are not clearly established.
We retrospectively collected data from a cohort of 268 patients with HCA managed in our tertiary center, from 1984 to 2020 and focused on clinical bleeding. Hemorrhage was considered severe when it required intensive care and moderate when bleeding symptoms required a hospitalization. We included 261 patients, of whom 130 (49.8%) had multiple HCAs or liver adenomatosis. All surgical specimen and liver biopsy were reviewed by an experienced liver pathologist and reclassified in the light of the current immunohistochemistry. Mean duration of follow-up was 93.3 months (range 1-363). We analyzed type, frequency, consequences of bleeding, and risk factors among clinical data and HCA characteristics.
Eighty-three HCA (31.8%) were hemorrhagic. There were 4 pregnant women with 1 newborn death. One patient died before treatment. Surgery was performed in 78 (94.0%) patients. Mortality was nil and severe complications occurred in 11.5%. Multivariate analysis identified size (OR 1.02 [1.01-1.02], P < 0.001), shHCA (OR 21.02 [5.05-87.52], P < 0.001), b-catenin mutation on exon 7/8 (OR 6.47 [1.78-23.55], P = 0.0046), chronic alcohol consumption (OR 9.16 [2.47-34.01], P < 0.001) as independent risk factors of clinical bleeding.
This series, focused on the hemorrhagic risk of HCA, shows that size, but rather more molecular subtype is determinant in the natural history of HCA.
本研究旨在确定肝细胞腺瘤(HCA)临床出血的独立危险因素,以制定更好的管理策略。
HCA 是一种罕见的良性肝肿瘤,其严重并发症包括恶性转化(罕见,5%-8%)和更常见的出血(20%-27%)。迄今为止,仅肿瘤大小>5cm 和组织学亚型(可能为 sonic hedgehog)与出血相关,但这些标准尚不清楚。
我们回顾性收集了 1984 年至 2020 年在我们的三级中心治疗的 268 例 HCA 患者的数据,并重点关注临床出血情况。当出血需要重症监护时,我们认为其为严重出血,当出血症状需要住院治疗时,我们认为其为中度出血。我们纳入了 261 例患者,其中 130 例(49.8%)患有多个 HCA 或肝腺瘤病。所有手术标本和肝活检均由经验丰富的肝脏病理学家进行评估,并根据当前的免疫组织化学重新分类。中位随访时间为 93.3 个月(范围 1-363 个月)。我们分析了临床数据和 HCA 特征中的出血类型、频率、后果和危险因素。
83 例 HCA(31.8%)发生出血。有 4 例孕妇,其中 1 例新生儿死亡。1 例患者在治疗前死亡。78 例(94.0%)患者接受了手术。无死亡病例,严重并发症发生率为 11.5%。多变量分析确定了肿瘤大小(OR 1.02[1.01-1.02],P<0.001)、shHCA(OR 21.02[5.05-87.52],P<0.001)、外显子 7/8 上 b-连环蛋白突变(OR 6.47[1.78-23.55],P=0.0046)和慢性酒精摄入(OR 9.16[2.47-34.01],P<0.001)是临床出血的独立危险因素。
本研究集中于 HCA 的出血风险,结果表明,肿瘤大小,但更倾向于分子亚型是 HCA 自然史的决定因素。